Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

What You Need to Know About Relay Therapeutics

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:BioPharma

Based in Cambridge, MA and founded in February 2016, Relay Therapeutics focuses on developing therapeutics based on protein motion. Source: BioSpace

Continue ReadingWhat You Need to Know About Relay Therapeutics

Busy Takeda Takes Out Tigenix in $630M Deal

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:BioPharma

Shares of TiGenix shot up more than 72 percent in pre-market trading after the deal was announced. Source: BioSpace

Continue ReadingBusy Takeda Takes Out Tigenix in $630M Deal

Pernix Takes the Ax to 22% of Workforce in Reorg

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:BioPharma

The company will undergo a reorganization that includes the termination of a number of sales representatives. Source: BioSpace

Continue ReadingPernix Takes the Ax to 22% of Workforce in Reorg

Longtime CEO at Bay Area's OncoMed Steps Down

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:BioPharma

Board of Directors has initiated search to identify successor. Source: BioSpace

Continue ReadingLongtime CEO at Bay Area's OncoMed Steps Down

KBP Biosciences Lands $76M, an Ex-GlaxoSmithKline Exec as Its New CEO and a HQ Move to Philly

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:BioPharma

The financing was co-led by Advantech Capital and SDIC Venture Capital. Source: BioSpace

Continue ReadingKBP Biosciences Lands $76M, an Ex-GlaxoSmithKline Exec as Its New CEO and a HQ Move to Philly

3 Biotechs That Could Outperform in 2018

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:BioPharma

A look at why investors should stock up on Amgen, Celldex Therapeutics, and Novavax soon. Source: BioSpace

Continue Reading3 Biotechs That Could Outperform in 2018

BioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossifica…

  • Post author:Sam
  • Post published:January 4, 2018
  • Post category:BioPharma

FOP is a very rare disease that affects approximately 1 in 2 million people worldwide. Source: BioSpace

Continue ReadingBioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossifica…

Bay Area's ChemoCentryx Gets Up to $100M in New Capital Commitments

  • Post author:Sam
  • Post published:January 3, 2018
  • Post category:BioPharma

The additional capital is expected to provide funding to advance avacopan through topline data from the Phase III ADVOCATE trial as well as potential registration filings in the U.S. and…

Continue ReadingBay Area's ChemoCentryx Gets Up to $100M in New Capital Commitments

Stoke Therapeutics Comes Out of Seed Mode With $40M and Ex-Sarepta CEO at Its Helm

  • Post author:Sam
  • Post published:January 3, 2018
  • Post category:BioPharma

The Series A round was entirely funded by founding investor Apple Tree Partners. Source: BioSpace

Continue ReadingStoke Therapeutics Comes Out of Seed Mode With $40M and Ex-Sarepta CEO at Its Helm

Triumvira Names a New CEO

  • Post author:Sam
  • Post published:January 3, 2018
  • Post category:BioPharma

Dr. Lammers brings more than 27 years of experience in product and clinical development spanning the pharmaceutical and biotechnology industries. Source: BioSpace

Continue ReadingTriumvira Names a New CEO
  • Go to the previous page
  • 1
  • …
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • …
  • 288
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.